骨化三醇联合贝那普利治疗原发性IgA肾病的临床观察

目的：观察骨化三醇联合贝那普利治疗原发性IgA肾病的临床疗效及安全性。方法：将60例原发性IgA肾病且24小时尿蛋白定量1．0～3．0g的患者随机分为贝那普利组（ACEI组）、骨化三醇联合贝那普利治疗组（VD3＋ACEI组）各30例，观察治疗12周，检测治疗前后24小时尿蛋白定量、血清肌酐、尿素氮、血钾及血钙。结果：两组治疗后尿蛋白定量均较治疗前下降，差异有统计学意义（P〈0．01），且VD3＋ACEI组较ACEI组下降更明显，差异有统计学意义（P〈0．05）。结论：骨化三醇联合贝那普利治疗可降低原发性IgA肾病患者的尿蛋白，未发现高血钾、高血钙不良反应发生。

Calcitriol combined with benazepril treatment clinical observation for primary IgA nephropathy

Objective：To observe the effectand safety of calcitriol combined with benazepril treatment for primary IgA nephropathy. Methods：Sixty cases with primary IgA nephropathy and 24 hours urine protein quantitative in 1.0 - 3.0g were randomly divided into the benazepril group（ACEI group ）,calcitriol combined with benazepril treatment group （VD3 ＋ ACEI group） 30 cases each,to observe treatment for 12 weeks,24 hours urine protein quantitative,serum creatinine, blood urea nitrogen,potassium and calcium were measured before and after the treatment.Results：In two groups after treatment, urine protein quantitative was significantly decreased,the difference was statistically significant（P〈 0.01）,and in VD3 ＋ ACEI group was decreased more obviously than in ACEI group,the difference was statistically significant（P 〈 0.05）.Conclusion：Calcitriol combined with benazepril treatment can reduce urine protein in patients with primary IgA nephropathy,no high potassium,high blood calcium found adverse reactions occur.